AntiobesityResearch.com

A Researcher's Resource for Obesity Therapeutics 


        
CNS: Miscellaneous

      		
    

  



    

    
 MOLECULAR TARGETS 
     

    
    

        

            Molecule
            Obesity/IR?
            Remarks [references]
           
        
 
         
            Orexins
            Increase
             [5,6,13,46-49] 
        
    
        
 
           BDNF
            Decrease
            [5,25,50,51]
        

        
 
           CNTF
            Decrease
            [22,25,52-55] 
        

        
 
           CART
            Mixed
             Depends on brain loci [1,5,37,38] 
        

        
 
           Galanin
            Increase
            [13,23,25,33,44,46]
        

                
 
           Galanin-like Peptide
            Increase
            [13,23,31]
            
            
 
           QRFP
            Increase
            [11,21,36] 
        

        
 
           Opiods
            Increase
            [2,12]
        

                       
 
           GABA
            Increase
            [1,26,27,56]
            

        
 
           GAD2
            Increase
            [4,39]
        

                
 
           ikkβ
            Increase
            [24]
        

 
        
 
           CA
            Increase
            [1,20]
        

                
 
           Glutamate
            Increase
            [1,27]
            
            
 
           Prolactin
            Increase
            [3,25]
            

                       
 
           Relaxin
            Increase
            [7,15]
                
 
           Nesfatin
            Decrease
            [17,18]
            

            
 
           Neuromedin
            Decrease
            [10,25]
       

    

    
    
    

    
              


    
        
 COMMERCIAL: LEADS --> PRODUCTS 
     

    
        

        

            Target
            Compound
            Company  (remarks) [references]
           
        

        
 
         
            CNTF
            Axokine
             Regeneron [22] 
        
    
        
 
           GABA-R,CA,Glutamate-R
            Topiramate
            J&J [9,12]
        

        
 
            AdRL, GABA-R,CA,Glutamate-R
            Qnexa 
             Vivus (phentermine+topiramate) [2,9,12,45]
        
    
        
 
           5HT & DA
            Zonisamide
            Eisai [12]
         
 
            NE-RU,DA-RU,OR
            Contrave 
             Orexigen (bupropion+naloxone) [2,12,44,59]
        
    
        
 
           NE-RU,DA-RU,5HT,DA
            Empatic
            Orexigen (buproprion+zonisamide)[1,12,59]   
        

    



 



       Abbreviations: AdRL=adrenergic release; RL=release;
RU=reuptake; RUI=reuptake inhibitor; OR=opiod receptor; ????=unknown; N/K=not known 
      




    

    
              
   
    
 References
     


    

        

         
        


1. Adan
RA, Vanderschuren LJ, E la Fleur S Anti-obesity drugs and neural circuits
of feeding..
Trends Pharmacol Sci. 2008;:208-17.



2. Aronne LJ,
Thornton-Jones ZD. New targets for obesity
pharmacotherapy. Clin
Pharmacol Ther. 2007 May;81(5):748-52.           



3. Ben-Jonathan N, Hugo
ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic
hormone. Trends Endocrinol
Metab. 2006 Apr;17(3):110-6.



4. Boutin P, Dina C,
Vasseur F, Dubois S, Corset L, et al. GAD2 on chromosome 10p12 is a candidate
gene for human obesity. PLoS
Biol. 2003 Dec;1(3):E68.



5. Dhillo WS. Appetite regulation: an overview. Thyroid. 2007
May;17(5):433-45.



6. Halford JC, Harrold JA,
Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs : effects on
appetite expression and use for the treatment of obesity. Drugs. 2007;67(1):27-55.



7. Halls ML, van der
Westhuizen ET, Bathgate RA, Summers RJ. Relaxin family peptide
receptors--former orphans reunite with their parent ligands to activate
multiple signalling pathways.
Br J Pharmacol. 2007 Mar;150(6):677-91.



8. Heal DJ, Smith SL,
Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands:
progress in the development of a novel pharmacological approach to the
treatment of obesity and related metabolic disorders. Pharmacol Ther. 2008 Feb;117(2):207-31.



9. Ioannides-Demos LL,
Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.



10. Jethwa PH, Small CJ,
Smith KL, Seth A, Darch SJ, Abbott CR, Murphy KG, Todd JF, Ghatei MA, Bloom SR.
Neuromedin U has a physiological role
in the regulation of food intake and partially mediates the effects of leptin. Am J Physiol Endocrinol Metab. 2005
Aug;289(2):E301-5.



11. Kampe J,
Wiedmer P, Pfluger PT, et al. Effect of central administration of QRFP(26) peptide on energy balance and
characterization of a second QRFP receptor in rat. Brain Res. 2006 Nov
13;1119(1):133-49



12. Kushner RF. Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50



13. Leibowitz
SF. Regulation and effects of hypothalamic
galanin: relation to dietary fat, alcohol ingestion, circulating lipids and
energy homeostasis. Neuropeptides. 2005 Jun;39(3):327-32



14. McGowan BM, Stanley SA, Donovan J, Thompson EL, Patterson M,
Semjonous NM, Gardiner JV, Murphy KG, Ghatei MA, Bloom SR.Relaxin-3 stimulates the hypothalamic-pituitary-gonadal
axis.  Am J Physiol
Endocrinol Metab. 2008 Aug;295(2):E278-86.



15. McGowan BM, Stanley SA, White NE, Spangeus A, Patterson M, Thompson EL,
Smith KL, Donovan J, Gardiner JV, Ghatei MA, Bloom SR.Hypothalamic mapping of orexigenic action and Fos-like
immunoreactivity following relaxin-3 administration in male Wistar rats. Am
J Physiol Endocrinol Metab. 2007 Mar;292(3):E913-9.



16. Meister
B Neurotransmitters in key neurons of the
hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007; 92:263-71.



17. Myers MG Jr. Keeping the fat off with nesfatin. Nat Med. 2006 Nov;12(11):1248-9.



18. Oh-I S, Shimizu H,
Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto
K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identification of nesfatin-1 as a
satiety molecule in the hypothalamus. Nature. 2006 Oct 12;443(7112):709-12.



19. Rivera G, Bocanegra-GarcÕa
V, Galiano S, Cirauqui N, et al. Melanin-concentrating hormone receptor
1 antagonists: a new perspective for the pharmacologic treatment of obesity. Curr Med Chem. 2008;15:1025-43.



20. Supuran CT. Carbonic anhydrases: novel therapeutic
applications for inhibitors and activators. Nat Rev Drug Discov. 2008 Feb;7(2):168-81.



21. Takayasu S, Sakurai
T, Iwasaki S, Teranishi H, et al.  A neuropeptide ligand of the G
protein-coupled receptor GPR103 regulates feeding, behavioral arousal, and
blood pressure in mice. Proc
Natl Acad Sci U S A. 2006 May 9;103(19):7438-43.




22. Vincent RP, le Roux
CW. New agents in development for the
management of obesity. Int J
Clin Pract. 2007 Dec;61(12):2103-12.



23. Williams
G, Cai XJ, Elliott JC, Harrold JA. Anabolic neuropeptides. Physiol Behav. 2004;81:211-22.



24. Zhang X, Zhang G, Zhang H,
Karin M, Bai H, Cai D. Hypothalamic IKKbeta/NF-kappaB and ER
stress link overnutrition to energy imbalance and obesity. Cell. 2008 Oct 3;135(1):61-73.



25. Nisoli E, Carruba MO. Emerging aspects of pharmacotherapy for
obesity and metabolic syndrome.
Pharmacol Res. 2004 Nov;50(5):453-69



26. Depoortere I. Targeting the ghrelin receptor to regulate food intake. Regul Pept. 2009 Apr 10.



27. Meister
B Neurotransmitters in key neurons of the
hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007; 92:263-71.





 28. Adamantidis A, de
Lecea L.The hypocretins as sensors for
metabolism and arousal. J
Physiol. 2009 Jan 15;587(Pt 1):33-40.



29. Brailoiu GC, Dun SL,
Brailoiu E, Inan S, Yang J, Chang JK, Dun NJ. Nesfatin-1: distribution and
interaction with a G protein-coupled receptor in the rat brain. Endocrinology. 2007 Oct;148(10):5088-94.



30. Colmers WF. Less fat with nesfatin. Trends Endocrinol Metab. 2007;18(4):131-2.



31. Kageyama H, Takenoya F, Kita T, Hori T, Guan JL, Shioda S. Galanin-like peptide in the brain:
effects on feeding, energy metabolism and reproduction. Regul Pept. 2005;126(1-2):21-



32. Lane MD, Wolfgang M, Cha SH, Dai Y. Regulation of food intake and energy
expenditure by hypothalamic malonyl-CoA. Int J Obes (Lond). 2008 Sep;32 Suppl 4:S49-54.



33. Arora S, Anubhuti. Role of neuropeptides in appetite
regulation and obesity--a review.  Neuropeptides.
2006;40(6):375-401.



34. McGowan BM, Stanley
SA, Smith KL,  et al. Central relaxin-3 administration causes
hyperphagia in male Wistar rats. Endocrinology. 2005 Aug;146(8):3295-300.




35. McGowan BM, Stanley
SA, Smith KL,et al.Effects of acute and chronic relaxin-3
on food intake and energy expenditure in rats. Regul Pept. 2006 Sep 11;136(1-3):72-7.




36. Patel SR, Murphy KG, Thompson EL, Patterson M, et al.  Pyroglutamylated RFamide peptide 43
stimulates the hypothalamic-pituitary-gonadal axis via gonadotropin-releasing
hormone in rats. Endocrinology.
2008 Sep;149(9):4747-54.



37. Smith KL, Gardiner JV, Ward HL, et al. Overexpression of CART in the PVN
increases food intake and weight gain in rats. Obesity (Silver Spring). 2008 Oct;16(10):2239-44.



38. Vicentic J, Jones DC.
The CART (cocaine- and
amphetamine-regulated transcript) system in appetite and drug addiction. Pharmacol Exp Ther. 2007;320(2):499-506.



39. Boutin P, Froguel P. GAD2: a polygenic contribution to
genetic susceptibility for common obesity? Pathol Biol (Paris). 2005 Jul;53(6):305-7.



40. Lectez B, Jeandel L,
El-Yamani FZ, Arthaud S,et al. The Orexigenic Activity of the
Hypothalamic Neuropeptide 26RFa is Mediated by the Neuropeptide Y and
Proopiomelanocortin Neurons of the Arcuate Nucleus. Endocrinology. 2009 Jan 22. [Epub ahead of print]



41. Matsushita H,
Ishihara A, Mashiko S, Tanaka T, Kanno T, Iwaasa H, Ohta H, Kanatani A. Chronic intracerebroventricular
infusion of nociceptin/orphanin FQ produces body weight gain by affecting both
feeding and energy metabolism in mice. Endocrinology. 2009 Feb 5.



42. Mounien L, Do Rego
JC, Bizet P, Boutelet I, Gourcerol G, et al. Pituitary adenylate cyclase-activating
polypeptide inhibits food intake in mice through activation of the hypothalamic
melanocortin system.
Neuropsychopharmacology. 2009 Jan;34(2):424-35.



43. Vazquez MJ, Gonz‡lez
CR, Varela L, Lage R, et al. Central resistin regulates hypothalamic
and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology. 2008 Sep;149(9):4534-43.



44. Orexigen press release. Orexigen Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions. Accessed: 7-1-09



45. Vivus press release. VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes. Accessed: 7-1-09



46. Dozio E, Ruscica M,
Motta M, Magni P. Hypothalamic neuropeptide systems as
targets for potential anti-obesity drugs. Mini Rev Med Chem. 2007 Jan;7(1):11-9.



Knutson KL, Van
Cauter E. Associations between sleep loss and
increased risk of obesity and diabetes. Ann N Y Acad Sci. 2008;1129:287-304.



47. Leibowitz SF. Overconsumption of dietary fat and
alcohol: mechanisms involving lipids and hypothalamic peptides. Physiol Behav. 2007 Aug 15;91(5):513-21.



48. Masaki T, Chiba S,
Yasuda T, Noguchi H, Kakuma T, Watanabe T, Sakata T, Yoshimatsu H. Involvement of hypothalamic histamine
H1 receptor in the regulation of feeding rhythm and obesity. Diabetes. 2004;53(9):2250-60.




49. Zheng
H, Corkern M, Stoyanova I, Patterson LM, et al. Peptides that regulate food intake:
appetite-inducing accumbens manipulation activates hypothalamic orexin neurons
and inhibits POMC neurons. Am J Physiol
2003;284:R1436-44.



50. Bariohay B, Lebrun B,
Moyse E, Jean A. Brain-derived neurotrophic factor plays
a role as an anorexigenic factor in the dorsal vagal complex. Endocrinology. 2005 Dec;146(12):5612-20.



51. Lee YS. The role of leptin-melanocortin system
and human weight regulation: lessons from experiments of nature. Ann Acad Med Singapore. 2009 Jan;38(1):34-11.



52. Cooke D, Bloom S. The obesity pipeline: current
strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006 Nov;5(11):919-31.



53. Cota D, Matter EK,
Woods SC, Seeley RJ The role of hypothalamic mammalian
target of rapamycin complex 1 signaling in diet-induced obesity. J Neurosci. 2008 Jul 9;28(28):7202-8.



54. Lage R, Dieguez C,
Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating
whole-body energy homeostasis. Trends Mol Med. 2008
Dec;14(12):539-49.




55. Xue B, Kahn BB. AMPK integrates nutrient and hormonal
signals to regulate food intake and energy balance through effects in the
hypothalamus and peripheral tissues. J Physiol. 2006 Jul 1;574(Pt 1):73-83.






56. Qiu J, Xue C, Bosch
MA, Murphy JG, Fan W, RÀnnekleiv OK, Kelly MJ. Serotonin 5-hydroxytryptamine2C
receptor signaling in hypothalamic proopiomelanocortin neurons: role in energy
homeostasis in females. Mol
Pharmacol. 2007 Oct;72(4):885-96



57. Lyn TE. Allergy drugs may fight diabetes, obesity. Reuters, Accessed: 9-17-09



58. Muzumdar RH, Huffman
DM, Atzmon G, Buettner C, Cobb LJ, Fishman S, Budagov T, Cui L, Einstein FH,
Poduval A, Hwang D, Barzilai N, Cohen P. Humanin: a novel central regulator of
peripheral insulin action.
PLoS One. 2009 Jul 22;4(7):e6334.



59. OrexigenAddressing the 
Growing Gap in Obesity Treatmen Orexigen Website, Accessed: 9-17-09